Ondansetron
- Generic Name
- Ondansetron
- Brand Names
- Zofran, Zuplenz
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O
- CAS Number
- 99614-02-5
- Unique Ingredient Identifier
- 4AF302ESOS
- Background
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...
- Indication
In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum
- Associated Therapies
- -
Developing Individualized Strategies to Prevent Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT01393288
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01370408
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
- Conditions
- Interventions
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 307
- Registration Number
- NCT01362530
Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT01352130
- Locations
- 🇮🇳
Tata Memorial Hopsital, Mumbai, Maharashtra, India
Ondansetron Augmentation in Treatment-resistant OCD
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Institute of Neuroscience, Florence, Italy
- Target Recruit Count
- 21
- Registration Number
- NCT01303536
- Locations
- 🇮🇹
Institute of Neuroscience, Florence, Italy
Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Transcept Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT01275248
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
🇺🇸Southwestern Research, Inc., Beverly Hills, California, United States
🇺🇸Carman Research, Smyrna, Georgia, United States
Symptomatic Treatment of Acute Gastroenteritis
- Conditions
- Interventions
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- IRCCS Burlo Garofolo
- Target Recruit Count
- 356
- Registration Number
- NCT01257672
- Locations
- 🇮🇹
Dipartimento di Emergenza Pediatrica, Ospedale Giuseppe Moscati, Avellino, Italy
🇮🇹Dipartimento di Emergenza Pediatrica, P.O. Spedali Civili, Brescia, Italy
🇮🇹Dipartimento di Pediatria, Ospedale Castelli, Verbania, Novara, Italy
Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons
- Conditions
- Interventions
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 357
- Registration Number
- NCT01254877
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2011-11-18
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 105
- Registration Number
- NCT01169805
- Locations
- 🇰🇷
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 85
- Registration Number
- NCT01121042
- Locations
- 🇦🇺
Monash Alfred Psychiatry Research Centre (MAPrc), Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.